Non-invasive prenatal diagnosis of single gene disorders with enhanced relative haplotype dosage analysis for diagnostic implementation
Open Access
- 24 April 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0280976
Abstract
Non-invasive prenatal diagnosis of single-gene disorders (SGD-NIPD) has been widely accepted, but is mostly limited to the exclusion of either paternal or de novo mutations. Indeed, it is still difficult to infer the inheritance of the maternal allele from cell-free DNA (cfDNA) analysis. Based on the study of maternal haplotype imbalance in cfDNA, relative haplotype dosage (RHDO) was developed to address this challenge. Although RHDO has been shown to be reliable, robust control of statistical error and explicit delineation of critical parameters for assessing the quality of the analysis have not been fully addressed. We present here a universal and adaptable enhanced-RHDO (eRHDO) procedure through an automated bioinformatics pipeline with a didactic visualization of the results, aiming to be applied for any SGD-NIPD in routine care. A training cohort of 43 families carrying CFTR, NF1, DMD, or F8 mutations allowed the characterization and optimal setting of several adjustable data variables, such as minimum sequencing depth, type 1 and type 2 statistical errors, as well as the quality assessment of intermediate steps and final results by block score and concordance score. Validation was successfully performed on a test cohort of 56 pregnancies. Finally, computer simulations were used to estimate the effect of fetal-fraction, sequencing depth and number of informative SNPs on the quality of results. Our workflow proved to be robust, as we obtained conclusive and correctly inferred fetal genotypes in 94.9% of cases, with no false-negative or false-positive results. By standardizing data generation and analysis, we fully describe a turnkey protocol for laboratories wishing to offer eRHDO-based non-invasive prenatal diagnosis for single-gene disorders as an alternative to conventional prenatal diagnosis.Keywords
Funding Information
- AFM-Téléthon (AO2019-N°19832)
- Association Vaincre la Mucoviscidose (RC20200502668)
- Association Vaincre la Mucoviscidose (RC20160501598)
- Association Vaincre la Mucoviscidose (RC2013500852)
- Agence de la Biomédecine (R18155NN)
- Agence de la Biomédecine (R13188KK)
- Agence Gaétan Saleun (PA-CPR-11/17)
This publication has 41 references indexed in Scilit:
- Non‐invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next‐generation sequencing allows for a safer, more accurate, and comprehensive approachPrenatal Diagnosis, 2015
- Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal PlasmaThe Journal of Clinical Endocrinology & Metabolism, 2014
- Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysisThe Journal of Maternal-Fetal & Neonatal Medicine, 2014
- Noninvasive Prenatal Diagnosis of Monogenic Diseases by Targeted Massively Parallel Sequencing of Maternal Plasma: Application to β-ThalassemiaClinical Chemistry, 2012
- Implementing noninvasive prenatal fetal sex determination using cell-free fetal DNA in the United KingdomExpert Opinion on Biological Therapy, 2012
- Haplotype phasing: existing methods and new developmentsNature Reviews Genetics, 2011
- Noninvasive Fetal Sex Determination Using Cell-Free Fetal DNAJAMA, 2011
- Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the FetusScience Translational Medicine, 2010
- Fine-scale recombination rate differences between sexes, populations and individualsNature, 2010
- A high-resolution recombination map of the human genomeNature Genetics, 2002